A high mutational burden is associated with a good prognosis in CRC, and we speculate that MANS CRCs may respond to immune checkpoint inhibitors, as has been reported in MBD4-deficient uveal melanomas.17 This evidence concerns the gene MBD4 and tumor predisposition syndrome 2.